美国良性子宫切除术后新发持续性阿片类药物使用的预测因素
本研究基于美国全国保险索赔数据库2011至2016年数据,回顾性纳入114,260例良性子宫切除术且术前非阿片类药物常用者,其中93,906例(82.2%)接受围手术期阿片类药物处方,4,334例(4.6%)出现新发持续性阿片类药物使用。多因素分析显示年轻年龄、南部地区、术前精神与疼痛疾病、吸烟、手术并发症及围手术期处方特征与风险升高相关,微创子宫切除术和较近手术年份与风险降低相关。
要点
- 良性子宫切除术后新发持续性阿片类药物使用率为4.6%(4,334/93,906)。
- 年轻年龄(18-34岁)、南部地区、术前焦虑/关节炎、吸烟及手术并发症与风险升高相关。
- 微创子宫切除术(腹腔镜或经阴道)和较近手术年份与风险降低相关。
核心结论
- 子宫切除术后新发持续性阿片类药物使用与多种患者、手术及阿片类药物处方相关因素有关,考虑这些因素可能有助于患者咨询和围手术期处方的共享决策以降低持续性使用风险。
研究设计与样本
- 回顾性队列研究,使用经过验证的全国保险索赔数据库(IBM MarketScan Commercial Database),识别2011至2016年接受良性子宫切除术的女性。
- 排除术前365至31天已有阿片类药物常用者后,纳入围手术期(子宫切除术前30天至术后14天)接受阿片类药物处方者,评估新发持续性阿片类药物使用。
- 新发持续性使用定义为术后15至90天至少1次处方且术后91至365天至少1次处方。
- 采用多因素logistic回归分析人口学、临床、手术及阿片类药物处方相关因素。
主要发现
- 共识别114,260例良性子宫切除术且术前非阿片类药物常用者,其中93,906例(82.2%)接受至少1次围手术期阿片类药物处方;93,906例中4,334例(4.6%)出现新发持续性阿片类药物使用。
- 新发持续性使用风险升高相关因素:年轻年龄18-34岁(调整OR 1.97,95%CI 1.69-2.30)、南部地理区域(调整OR 2.03,95%CI 1.79-2.27)、术前焦虑(调整OR 1.20,95%CI 1.09-1.33)、关节炎(调整OR 1.30,95%CI 1.21-1.40)、围手术期处方超过1次(调整OR 1.53,95%CI 1.24-1.88)、心境障碍药物使用(调整OR 1.51,95%CI 1.40-1.64)、吸烟(调整OR 1.65,95%CI 1.45-1.89)及手术并发症(调整OR 1.84,95%CI 1.69-2.00)。
- 首次围手术期处方总吗啡毫克当量≥300时持续性使用可能性增加9%(95%CI 1.01-1.17),但未达统计学显著。
- 首次围手术期处方在手术前而非手术后发放使新发持续性使用风险增加61%(95%CI 1.50-1.72);处方覆盖的围手术期每增加1天,持续性使用可能性增加2%(95%CI 1.02-1.03)。
- 微创子宫切除术(腹腔镜:调整OR 0.89,95%CI 0.71-0.88;经阴道:调整OR 0.82,95%CI 0.72-0.93)和较近手术年份(2016年 vs 参照2011年:调整OR 0.58,95%CI 0.51-0.65)显著降低新发持续性使用可能性。
临床怎么用
- 作者认为,考虑这些因素可能有助于患者咨询和围手术期处方的共享决策,以降低持续性阿片类药物使用风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite substantial reductions in the past decade, prescription opioids continue to cause widespread morbidity and mortality in the United States. Little is known regarding patterns and predictors of opioid use among women undergoing benign hysterectomy. OBJECTIVE: This study aimed to identify the incidence and predictors of new persistent opioid use after benign hysterectomy among opioid-naïve women from a set of demographic, operative, and opioid prescription characteristics of patients. STUDY DESIGN: In this retrospective cohort study, we identified women undergoing benign hysterectomy from 2011 to 2016 using a validated national insurance claims database (IBM MarketScan Commercial Database). After excluding women with prevalent opioid use (from 365 to 31 days preoperatively), we identified patients who received a perioperative opioid prescription (30 days before to 14 days after hysterectomy) and evaluated them for new persistent opioid use, defined as at least 1 prescription from 15 to 90 days and at least 1 prescription from 91 to 365 days postoperatively. Multivariate logistic regression was used to examine demographic, clinical, operative, and opioid prescription-related factors associated with new persistent use. International Classification of Diseases, Ninth and Tenth Revisions, and Clinical Classification Software codes were used to identify hysterectomies, preoperative pain and psychiatric diagnoses, surgical indications, and surgical complications included as covariates. RESULTS: We identified 114,260 women who underwent benign hysterectomy and were not prevalent opioid users, of which 93,906 (82.2%) received at least 1 perioperative opioid prescription. Of 93,906 women, 4334 (4.6%) developed new persistent opioid use. Logistic regression demonstrated that new persistent use odds is significantly increased by younger age (18-34 years; adjusted odds ratio, 1.97; 95% confidence interval, 1.69-2.30), southern geographic location (adjusted odds ratio, 2.03; 95% confidence interval, 1.79-2.27), preoperative psychiatric and pain disorders (anxiety: adjusted odds ratio, 1.20 [95% confidence interval, 1.09-1.33]; arthritis: adjusted odds ratio, 1.30 [95% confidence interval, 1.21-1.40]), >1 perioperative prescription (adjusted odds ratio, 1.53; 95% confidence interval, 1.24-1.88), mood disorder medication use (adjusted odds ratio, 1.51; 95% confidence interval, 1.40-1.64), tobacco smoking (adjusted odds ratio, 1.65; 95% confidence interval, 1.45-1.89), and surgical complications (adjusted odds ratio, 1.84; 95% confidence interval, 1.69-2.00). Although statistically nonsignificant, total morphine milligram equivalent of ≥300 in the first perioperative prescription increased persistent use likelihood by 9% (95% confidence interval, 1.01-1.17). Dispensing of a first perioperative prescription before the surgery, as opposed to after, increased new persistent use odds by 61% (95% confidence interval, 1.50-1.72). Each additional perioperative day covered by a prescription increased the likelihood of persistent use by 2% (95% confidence interval, 1.02-1.03). In contrast, minimally invasive hysterectomy (laparoscopic: adjusted odds ratio, 0.89 [95% confidence interval, 0.71-0.88]; vaginal: adjusted odds ratio, 0.82 [95% confidence interval, 0.72-0.93]) and a more recent surgery year (2016 vs reference 2011: adjusted odds ratio 0.58; 95% confidence interval, 0.51-0.65) significantly decreased its likelihood. CONCLUSION: New persistent opioid use after hysterectomy was associated with several patient, operative, and opioid prescription-related factors. Considering these factors may be beneficial in counseling patients and shared decision-making about perioperative prescription to decrease the risk of persistent opioid use.
引用
- AlAshqar A, Ishiwata R, Moss C, et al. Predictors of new persistent opioid use after benign hysterectomy in the United States. Am J Obstet Gynecol. 2022. PMID: 35248573. doi:10.1016/j.ajog.2022.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。